You are here

Eutropics Pharmaceuticals, Inc.

Company Information
Address
767 Concord Ave
Cambridge, MA 02138
United States



Information

UEI: VYD9LKBYHHQ3

# of Employees: 8


Ownership Information

HUBZone Owned: Yes

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Commercializing Praedicare Dx TM platform for guiding cancer treatments

    Amount: $2,989,986.00

    Abstract The Eutropics PraediCare Dxis an emerging clinical diagnostic assay that will be used to predict patient response to specific chemotherapiesUnlike existing assaysPraediCare Dxpredicts respons ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  2. Development of Praedicare Dx as CDx for AML Period of Performance: September 19, 2014 through September 18, 2015

    Amount: $1,499,743.00

    Not Available

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  3. IGF::OT::IGF OTHER FUNCTIONS TOPIC 277, DEVELOPING BH3 PROFILING AS A COMPANION DIAGNOSTIC FOR VELCADE TREATMENT FOR MULTIPLE MYELOMA

    Amount: $1,499,746.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Multiple Myeloma (MM) both to improve efficacy and reduce unn ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  4. IGF::OT::IGF OTHER FUNCTIONS RandD- BIOMEDICAL (BASIC RESEARCH)

    Amount: $199,892.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating Acute Myelogenous Leukemia (AML) both to improve efficacy and ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  5. BH3 Profiling as a Companion Diagnostic For Velcade

    Amount: $199,860.00

    There is a clear need to better define patient-specific treatment strategies for the use of both standard and novel therapies for treating multiple myeloma. Eutropics is uniquely positioned to improve ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  6. Development of small molecule inhibitor of Mcl-1 for cancer treatment

    Amount: $1,357,720.00

    DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1 (Mcl-1), a member of this protein family, is a key regul ...

    SBIRPhase II2010Department of Health and Human Services National Institutes of Health
  7. Development of small molecule inhibitors of Mcl-1 for cancer treament

    Amount: $326,983.00

    DESCRIPTION (provided by applicant): The Bcl-2 family proteins are key effectors of cancers. Recent studies indicate that Myeloma cell factor-1(Mcl-1), a member of this protein family, is a key regu ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government